Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease marked by chronic fibrosis and a high mortality rate [1]. Emerging evidence implicates cellular senescence as a critical driver of IPF pathogenesis [2]. Recently, plant-derived compounds with senolytic activity have performed potential in selectively eliminating senescent cells, thereby mitigating fibrotic progression [3]. This review critically evaluates current preclinical evidence on plant-based senolytics, elucidates underlying molecular mechanisms, and discusses translational challenges and Advanced research directions. Experimental research combining traditional plant things along with current studies of aging science opens up the potential therapeutic model for the treatment of IPF [4].